Metformin monotherapy in lean women with polycystic ovary syndrome

Kumari, Anupama; Haq, Afrozul; Jayasundaram, R; Abdel-Wareth, LO; Haija, SA al; Alvares, Marion

doi:10.1016/s1472-6483(10)60809-7

Cited by 83 publications

(29 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is consistent with previous data from the literature (22)(23)(24)(25)(26)(27)(28). Specifically, Maciel et al (23) first demonstrated in a randomized controlled fashion that a 6-month course of 1500 mg/day of metformin decreased serum androgens and fasting insulin levels and improved menstrual cyclicity significantly better in nonobese than in obese PCOS patients.…”

Section: Discussionsupporting

confidence: 91%

Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome

Palomba

Falbo

Orio

et al. 2009

Fertility and Sterility

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome

Palomba

Falbo

Orio

et al. 2009

Fertility and Sterility

View full text Add to dashboard Cite

“…We can therefore propose that our results suggest an indirect effect of metformin both in the implantation process (by restoring serum E levels) and in corpus luteum development (by protecting the diminution of P levels). Moreover, previous reports have demonstrated the efficacy of metformin in regulating the hormonal pattern in women displayed during the hyperandrogenic process as PCOS (Vandermolen et al 2001;Harborne et al 2003b;Kazerooni and Dehghan-Kooshkghazi 2003;Weerakiet et al 2004;Kumari et al 2005). However, even when the hormonal environment is regulated and women with PCOS become pregnant after the induction of ovulation, they can develop defects in the luteal phase resulting in miscarriage (Homburg et al 1988), probably due to premature luteolysis.…”

Section: Discussionmentioning

confidence: 99%

Metformin prevents embryonic resorption induced by hyperandrogenisation with dehydroepiandrosterone in mice

Solano¹,

Elia²,

Luchetti³

et al. 2006

Reprod. Fertil. Dev.

View full text Add to dashboard Cite

The present study examined the mechanism by which metformin prevents dehydroepiandrosterone (DHEA)-induced embryonic resorption in mice. Treatment with DHEA (6 mg/100 g bodyweight, 24 and 48 h post implantation) induced 88 +/- 1 % embryonic resorption and the diminution of both serum oestradiol (E) and progesterone (P) levels. However, when metformin (50 mg/kg bodyweight) was given together with DHEA, embryo resorption (43 +/- 3% v. 35 +/- 5% in controls) and both serum E and P levels were not significantly different from controls. Glucose and insulin levels were increased in the DHEA-treated mice but when metformin was administered together with DHEA these parameters were similar to control values. Treatment with DHEA increased ovarian oxidative stress and diminished uterine nitric oxide synthase (NOS) activity; however, when metformin was administered together with DHEA, both ovarian oxidative stress and uterine NOS activity were not different from controls. Metformin treatment did not modify the percentage of CD4(+) and CD8(+) T cells from both axillar and retroperitoneal lymph nodes but prevented the increase of serum tumour necrosis factor +/- produced in DHEA-treated mice. These results show that metformin acts in DHEA-induced embryonic resorption in mice by modulating endocrine parameters, ovarian oxidative stress and uterine NOS activity.

show abstract

“…Furthermore, not only obese, but also lean women with PCOS can benefit from metformin therapy; in fact, the effects of metformin treatment on ovulation rate could even be greater in lean than in obese patients [99].…”

Section: Effect Of Metformin In the Polycystic Ovary Syndromementioning

confidence: 99%

Metformin Beyond Diabetes: New Life for an Old Drug

Rotella

Monami²,

Mannucci³

2006

CDR

View full text Add to dashboard Cite

Metformin is a widely used drug in the therapy of patients affected by diabetes mellitus. Although some caution is needed in the very old, advanced age per se does not represent a contraindication to metformin use. Despite the fact that its precise mechanism of action it is not completely elucidated, long-term treatment with this drug in monotherapy, improves glycaemic control and reduces cardiovascular mortality in overweight type 2 diabetic patients. Experimental evidence produced over the years suggests that metformin may be useful in some clinical conditions different from diabetes mellitus. In the present review we have examined currently available data about the possible use of metformin as an effective therapeutical agent in pathological conditions different from type 2 diabetes mellitus. On the basis of our investigation, the use of metformin can be suggested in overweigth patients affected by impaired glucose tolerance and/or fasting hyperglycaemia and in subjects affected by polycystic ovary syndrome, while further data are needed in order to prescribe such a drug in patients affected by non-alcoholic steato-hepatitis and in HIV patients on antiretroviral therapy.

show abstract

Metformin monotherapy in lean women with polycystic ovary syndrome

Cited by 83 publications

References 18 publications

Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome

Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome

Metformin prevents embryonic resorption induced by hyperandrogenisation with dehydroepiandrosterone in mice

Metformin Beyond Diabetes: New Life for an Old Drug

Contact Info

Product

Resources

About